{"nctId":"NCT01419665","briefTitle":"GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)","startDateStruct":{"date":"2011-12-01","type":"ACTUAL"},"conditions":["Follicular Lymphoma"],"count":629,"armGroups":[{"label":"GP2013","type":"EXPERIMENTAL","interventionNames":["Biological: GP2013"]},{"label":"rituximab","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: rituximab"]}],"interventions":[{"name":"GP2013","otherNames":["no brand name available"]},{"name":"rituximab","otherNames":["MabThera(R)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient with previously untreated advanced stage, CD20-positive FL\n* Patient with ECOG performance status 0, 1 or 2.\n\nExclusion Criteria:\n\n* Patient with Grade 3b (aggressive) FL or any histology other than FL grade 1, 2 or 3a\n* Patient who has previously received any prior therapy for lymphoma\n* Patient with evidence of any uncontrolled, active infection (viral, bacterial or fungal).\n* Patient with any malignancy within 5 years prior to date of randomization, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer.\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate (ORR)","description":"ORR is defined as the proportion of patients whose best overall disease response was either CR or PR during the combination treatment period based on blinded independent central radiology review.","paramType":"NUMBER","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.1","spread":null},{"groupId":"OG001","value":"87.5","spread":null}]}]}]},{"type":"SECONDARY","title":"To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"To Evaluate the Partial Response (PR) Rate During the Combination Treatment Period","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"225","spread":null},{"groupId":"OG001","value":"232","spread":null}]}]}]},{"type":"SECONDARY","title":"To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization","description":"Number of participants with progression free survival events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]}]},{"type":"SECONDARY","title":"To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths","description":"OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, OS was censored at the date of last contact including survival follow-up.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)","description":"number of participants with confirmed positive ADA","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Max)","description":"C max\n\nFor descriptive purposes only, no hypothesis testing","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"333.59","spread":"41.09"},{"groupId":"OG001","value":"331.93","spread":"35.32"}]}]}]},{"type":"SECONDARY","title":"To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Trough)","description":"C through\n\nFor descriptive purposes only, no hypothesis testing","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.42","spread":"47.593"},{"groupId":"OG001","value":"82.13","spread":"61.526"}]}]}]},{"type":"SECONDARY","title":"To Evaluate a PD Marker (Peripheral CD19+ B-cell Counts) Following the Treatment With GP2013 + Chemotherapy Amd MabThera- Chemotherapy","description":"AUEC (0-21d)\n\nFor descriptive purposes only, no hypothesis testing","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1790","spread":"23.5"},{"groupId":"OG001","value":"1910","spread":"13.3"}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 30 months (treatment duration ranged from 90 to 782 days) Deaths post treatment survival follow up were collected after the on- treatment period, up to 3 years.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":71,"n":312},"commonTop":["Neutropenia","Constipation","Cough","Nausea","Diarrhoea"]}}}